[Effect of anti-CD4+ human/murine chimeric antibody on the proliferation and apoptosis of lymphocyte in patients with asthma].
To investigate the effects of anti-CD4+ human/murine chimeric antibody on the proliferation and the apoptosis of peripheral blood lymphocytes (PBL) in patients with asthma. PBL isolated from patients with asthma were cultured with 50 mg/L, 100 mg/L anti-CD4+ human/murine chimeric antibody and anti-CD3+ McAb (10 mg/L) for 0, 24, 48 h in vitro, the apoptosis cell percentage were detected by flow cytometry and in situ end-labeling technique of fragmental DNA as well as the proliferation of PBL were detected by MTT method. Comparing with normal controls, the apoptosis cell percentage was significantly decreased by stimulation with anti-CD3+ McAb for 24 h and 48 h, the proliferation of lymphocyte was increased in patients with asthma; the apoptosis cell percentage of patients with asthma was significantly increased (P < 0.01, respectively) with the cell cultured with 50 mg/L or 100 mg/L anti-CD4+ human/murine chimeric antibody for 24 h or 48 h At the same time the lymphocyte proliferation was inhabited (P < 0.01, respectively). It is demonstrated that the proliferation of PBL in patients with asthma were increased and the apoptosis cell percentage were decreased, anti-CD4+ human/murine chimeric antibody had inhibited the proliferation of T lymphocyte and had enhanced the T lymphocyte apoptosis. The anti-CD4+ human/murine chimeric antibody may be potentially useful for the biotherapy of asthma.